BUZZ-Icon falls on downbeat 2025 profit, revenue forecasts

Reuters

01-14

BUZZ-Icon falls on downbeat 2025 profit, revenue forecasts

** Shares of Icon ICLR.O fall 8.5% to $199.50 premarket

** Contract research firm sees its 2025 adj EPS between $13 and $15

** The midpoint is lower than Wall Street estimates of $14.83 - LSEG

** The midpoint of co's 2025 rev outlook of $8.05 bln-$8.65 bln is also lower than estimates of $8.50 bln

** "Icon continues to navigate dynamic clinical development market conditions, as trial activity has been impacted by cautious spending from biopharma customers, in both the biotech and large pharma businesses," CEO Steve Cutler says

** "Overall, the guidance reflects a still-hesitant demand environment across both pharma and biotech, which will likely last for an additional 2-4 quarters" - brokerage Evervore ISI

** Co reaffirms 2024 adj EPS and rev outlooks

** ICLR stock fell 25.9% in 2024

(Reporting by Puyaan Singh)

((Puyaan.Singh@thomsonreuters.com;))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2503575095"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503575095\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2503575095?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-14 22:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503575095","market":"us","top_or_hot":-1,"title":"BUZZ-Icon falls on downbeat 2025 profit, revenue forecasts","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Icon falls on downbeat 2025 profit, revenue forecasts</title></head><body><p>** Shares of Icon <span>ICLR.O</span> fall 8.5% to $199.50 premarket</p><p>** Contract research firm sees its <span>2025 adj EPS</span> between $13 and $15</p><p>** The midpoint is lower than Wall Street estimates of $14.83 - LSEG</p><p>** The midpoint of co's 2025 rev outlook of $8.05 bln-$8.65 bln is also lower than estimates of $8.50 bln</p><p>** \"Icon continues to navigate dynamic clinical development market conditions, as trial activity has been impacted by cautious spending from biopharma customers, in both the biotech and large pharma businesses,\" CEO Steve Cutler says</p><p>** \"Overall, the guidance reflects a still-hesitant demand environment across both pharma and biotech, which will likely last for an additional 2-4 quarters\" - brokerage Evervore ISI</p><p>** Co reaffirms 2024 adj EPS and rev outlooks</p><p>** ICLR stock fell 25.9% in 2024</p><p> (Reporting by Puyaan Singh)</p><p> ((Puyaan.Singh@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Icon falls on downbeat 2025 profit, revenue forecasts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Icon falls on downbeat 2025 profit, revenue forecasts\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-01-14 22:08</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Icon falls on downbeat 2025 profit, revenue forecasts</title></head><body><p>** Shares of Icon <span>ICLR.O</span> fall 8.5% to $199.50 premarket</p><p>** Contract research firm sees its <span>2025 adj EPS</span> between $13 and $15</p><p>** The midpoint is lower than Wall Street estimates of $14.83 - LSEG</p><p>** The midpoint of co's 2025 rev outlook of $8.05 bln-$8.65 bln is also lower than estimates of $8.50 bln</p><p>** \"Icon continues to navigate dynamic clinical development market conditions, as trial activity has been impacted by cautious spending from biopharma customers, in both the biotech and large pharma businesses,\" CEO Steve Cutler says</p><p>** \"Overall, the guidance reflects a still-hesitant demand environment across both pharma and biotech, which will likely last for an additional 2-4 quarters\" - brokerage Evervore ISI</p><p>** Co reaffirms 2024 adj EPS and rev outlooks</p><p>** ICLR stock fell 25.9% in 2024</p><p> (Reporting by Puyaan Singh)</p><p> ((Puyaan.Singh@thomsonreuters.com;))</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ICLR","symbol_name":"ICON plc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nL4N3OA14B:1","article_id":"2503575095","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503575095","pubTimestamp":1736863707,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Icon falls on downbeat 2025 profit, revenue forecasts** Shares of Icon ICLR.O fall 8.5% to $199.50 premarket** Contract research firm sees its 2025 adj EPS between $13 and $15** The midpoint is lower than Wall Street estimates of $14.83 - LSEG** The midpoint of co's 2025 rev outlook of $8.05 bln-$8.65 bln is also lower than estimates of $8.50 bln** \"Icon continues to navigate dynamic clinical development market conditions, as trial activity has been impacted by cautious spending from biopharma customers, in both the biotech and large pharma businesses,\" CEO Steve Cutler says** \"Overall, the guidance reflects a still-hesitant demand environment across both pharma and biotech, which will likely last for an additional 2-4 quarters\" - brokerage Evervore ISI** Co reaffirms 2024 adj EPS and rev outlooks** ICLR stock fell 25.9% in 2024  ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ICLR":"ICON plc"},"translate_title":"BUZZ-Icon因2025年利润和收入预测悲观而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ICLR":0.9},"content_text":"BUZZ-Icon falls on downbeat 2025 profit, revenue forecasts** Shares of Icon ICLR.O fall 8.5% to $199.50 premarket** Contract research firm sees its 2025 adj EPS between $13 and $15** The midpoint is lower than Wall Street estimates of $14.83 - LSEG** The midpoint of co's 2025 rev outlook of $8.05 bln-$8.65 bln is also lower than estimates of $8.50 bln** \"Icon continues to navigate dynamic clinical development market conditions, as trial activity has been impacted by cautious spending from biopharma customers, in both the biotech and large pharma businesses,\" CEO Steve Cutler says** \"Overall, the guidance reflects a still-hesitant demand environment across both pharma and biotech, which will likely last for an additional 2-4 quarters\" - brokerage Evervore ISI** Co reaffirms 2024 adj EPS and rev outlooks** ICLR stock fell 25.9% in 2024 (Reporting by Puyaan Singh) ((Puyaan.Singh@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}